Literature DB >> 23684102

MicroRNA-9 enhances migration and invasion through KLF17 in hepatocellular carcinoma.

Zhao Sun1, Qin Han, Na Zhou, Shihua Wang, Shan Lu, Chunmei Bai, Robert Chunhua Zhao.   

Abstract

Metastasis is one of the hallmarks of cancer malignancy that usually causes more detrimental effects than a primary tumor. Many microRNAs were reported to be involved in the process of tumor metastasis. Hep11 and Hep12 cells were derived from primary and recurrence (intrahepatic metastatic) sites of hepatocellular carcinoma (HCC), respectively. Hep12 exhibited a higher invasive and migratory potential than Hep11. There was also a significantly higher expression of miR-9 in Hep12 cells than in Hep11 cells. Further studies in HCC cell lines demonstrated that miR-9 could promote tumor cell migration and invasion. In addition, miR-9 downregulated KLF17 protein expression by targeting the 3'UTR region of the KLF17 gene directly. As a transcription factor, KLF17 directly acted on the promoters of EMT-related genes (ZO-1, Vimentin and Fibronectin (FN)) in HCC cell lines. Therefore, we conclude that miR-9 may possibly promote HCC migration and invasion through regulation of KLF17.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CHIP; E-ca; E-cadherin; EMT; FBS; FN; HBV; HCC; HNSCC; Hepatitis B virus; Hepatocellular carcinoma; Invasion; KLF-17; KLF17; Krüppel-like factor 17; MT; Vim; WT; chromatin immunoprecipitation; epithelial mesenchymal transition; fetal calf serum; fibronectin; head and neck squamous cell carcinoma; hepatocellular carcinoma; microRNA-9; mutant type; qRT-PCR; quantitative reverse transcription polymerase chain reaction; vimentin; wild type

Mesh:

Substances:

Year:  2013        PMID: 23684102      PMCID: PMC5528452          DOI: 10.1016/j.molonc.2013.04.007

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  30 in total

1.  Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression.

Authors:  Wen Wen; Jin Ding; Wen Sun; Jing Fu; Yao Chen; Kun Wu; Beifang Ning; Tao Han; Lei Huang; Cheng Chen; Dong Xie; Zhong Li; Gensheng Feng; Mengchao Wu; Weifen Xie; Hongyang Wang
Journal:  Hepatology       Date:  2012-04-25       Impact factor: 17.425

2.  MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility.

Authors:  Liang Zhu; Huarong Chen; Donger Zhou; Dan Li; Rui Bai; Shu Zheng; Weiting Ge
Journal:  Med Oncol       Date:  2011-05-12       Impact factor: 3.064

3.  Reduced expression of Krüppel-like factor 17 is related to tumor growth and poor prognosis in lung adenocarcinoma.

Authors:  Xing-dong Cai; Yan-bin Zhou; Li-xia Huang; Qing-li Zeng; Long-juan Zhang; Qin-qin Wang; Shao-li Li; Jian-qiang Feng; An-jia Han
Journal:  Biochem Biophys Res Commun       Date:  2012-01-03       Impact factor: 3.575

4.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

5.  Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis.

Authors:  Haiyan Yang; Jessica Rouse; Luanne Lukes; Mindy Lancaster; Timothy Veenstra; Ming Zhou; Ying Shi; Yeong-Gwan Park; Kent Hunter
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma.

Authors:  Fu-Yao Liu; Yue-Ling Deng; Yuan Li; Dan Zeng; Zhen-Zhen Zhou; De-An Tian; Mei Liu
Journal:  Med Oncol       Date:  2013-01-17       Impact factor: 3.064

7.  Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy.

Authors:  Xiaolan Xu; Baocai Xing; Meihao Hu; Zuoliang Xu; Yong Xie; Guanghai Dai; Jun Gu; Yu Wang; Zhiqian Zhang
Journal:  Cytotherapy       Date:  2010-04       Impact factor: 5.414

8.  The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor.

Authors:  Xiao-Lan Xu; Bao-Cai Xing; Hai-Bo Han; Wei Zhao; Mei-Hao Hu; Zuo-Liang Xu; Ji-You Li; Yong Xie; Jun Gu; Yu Wang; Zhi-Qian Zhang
Journal:  Carcinogenesis       Date:  2009-11-06       Impact factor: 4.944

9.  KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer.

Authors:  Kiranmai Gumireddy; Anping Li; Phyllis A Gimotty; Andres J Klein-Szanto; Louise C Showe; Dionyssios Katsaros; George Coukos; Lin Zhang; Qihong Huang
Journal:  Nat Cell Biol       Date:  2009-10-04       Impact factor: 28.824

10.  SNAI1 expression in colon cancer related with CDH1 and VDR downregulation in normal adjacent tissue.

Authors:  C Peña; J M García; M J Larriba; R Barderas; I Gómez; M Herrera; V García; J Silva; G Domínguez; R Rodríguez; J Cuevas; A G de Herreros; J I Casal; A Muñoz; F Bonilla
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

View more
  43 in total

1.  Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma.

Authors:  Zhenyu Wu; Liang Wang; Gang Li; Hui Liu; Feiyan Fan; Zhaobo Li; Yunqing Li; Guodong Gao
Journal:  Mol Cell Biochem       Date:  2013-12       Impact factor: 3.396

2.  MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.

Authors:  Adriana Sondermann; Flavia Maziero Andreghetto; Ana Carolina Bernardini Moulatlet; Elivane da Silva Victor; Marilia Germanos de Castro; Fábio Daumas Nunes; Lenine Garcia Brandão; Patricia Severino
Journal:  Clin Exp Metastasis       Date:  2015-05-26       Impact factor: 5.150

Review 3.  SP and KLF Transcription Factors in Digestive Physiology and Diseases.

Authors:  Chang-Kyung Kim; Ping He; Agnieszka B Bialkowska; Vincent W Yang
Journal:  Gastroenterology       Date:  2017-03-30       Impact factor: 22.682

4.  Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma.

Authors:  Yidong Liu; Haiou Liu; Liu Yang; Qian Wu; Weisi Liu; Qiang Fu; Weijuan Zhang; Haijian Zhang; Jiejie Xu; Jianxin Gu
Journal:  J Biol Chem       Date:  2017-01-06       Impact factor: 5.157

5.  Density-Dependent Regulation of Glioma Cell Proliferation and Invasion Mediated by miR-9.

Authors:  Mark Katakowski; Nicholas Charteris; Michael Chopp; Evgeniy Khain
Journal:  Cancer Microenviron       Date:  2016-12-14

Review 6.  Anti-miRNA oligonucleotides: A comprehensive guide for design.

Authors:  Joana Filipa Lima; Laura Cerqueira; Ceu Figueiredo; Carla Oliveira; Nuno Filipe Azevedo
Journal:  RNA Biol       Date:  2018-03-23       Impact factor: 4.652

7.  Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer.

Authors:  Bo Zhou; Hongbin Xu; Meng Xia; Chaoyang Sun; Na Li; Ensong Guo; Lili Guo; Wanying Shan; Hao Lu; Yifan Wu; Yuan Li; Degui Yang; Danhui Weng; Li Meng; Junbo Hu; Ding Ma; Gang Chen; Kezhen Li
Journal:  Front Med       Date:  2017-05-04       Impact factor: 4.592

8.  Krüppel-like factors 4 and 5 expression and their involvement in differentiation of oral carcinomas.

Authors:  Masaki Shibata; Tadashige Chiba; Takanori Matsuoka; Nozomi Mihara; Shuichi Kawashiri; Kazushi Imai
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

9.  Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overcome Tumorigenesis in Non-small Cell Lung Cancer.

Authors:  Amjad Ali; Muhammad Zeeshan Bhatti; Abdus Saboor Shah; Hong-Quan Duong; Huda Mohammad Alkreathy; Shah Faisal Mohammad; Rahmat Ali Khan; Ayaz Ahmad
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

10.  MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma.

Authors:  Yue-Yuan Lai; Fei Shen; Wen-Song Cai; Ji-Wei Chen; Jian-Hua Feng; Jie Cao; Huan-Qing Xiao; Guang-Hui Zhu; Bo Xu
Journal:  Tumour Biol       Date:  2016-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.